We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Affymetrix Signs Translational Medicine Agreement in China

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Affymetrix Signs Translational Medicine Agreement in China"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Affymetrix Inc. and Zhejiang California Nanosystem Institute (ZCNI) at Zhejiang University have announced that they have entered into a collaboration to develop clinical applications using GeneChip® technology.

Under terms of the agreement, ZCNI researchers will use Affymetrix GeneChip microarray technology for translational medicine research projects, beginning with cancer, newborn genetic diseases and infectious diseases.

In addition, the two organizations are establishing a joint laboratory that will support clinical researchers at Zhejiang University and its six affiliated hospitals.

The researchers will use Affymetrix GeneChip technology to analyze genomic information across large patient samples.

The data will enable them to discover RNA and DNA patterns that can classify, manage and treat clinically important diseases.

"We are excited about using the Affymetrix GeneChip technology to explore the relationship between genes and human health and to develop clinical applications to improve healthcare in China," said Professor Jiaan Cheng, director of ZCNI and former vice president of Research at Zhejiang University.

"This collaboration will enable us to develop a more personalized form of medicine, which should help improve healthcare in China and around the world."

"As an alumnus and a former faculty member of this distinguished University, I am very impressed by the cutting-edge research that is taking place at the ZCNI and the School of Medicine," said Wei Zhou, Ph.D. vice president, Intellectual Property and Advanced Technology and China Country Manager at Affymetrix.

"With this translational medicine strategic partnership and the joint laboratory, we hope to accelerate clinical research and bring better healthcare to patients."

Affymetrix collaborates with academic institutions, advocacy groups and the pharmaceutical and diagnostics community through its Translational Medicine Program to develop molecular signatures for improving patient care.

Affymetrix GeneChip microarray technology helps researchers to diagnose and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases.

The Translational Medicine Program complements the Powered by Affymetrix™ program, which enables companies to license GeneChip technology to create custom-designed microarray products based on signatures such as those of our translational medicine partners.

This technology is already being used in many applications, including diagnostics, forensics, animal, industrial and food testing.